Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis

A population pharmacokinetic (PK) and pharmacodynamic (PD) model was developed for inotersen to evaluate exposure–response relationships and to optimize therapeutic dosing regimen in patients with hereditary transthyretin (TTR) amyloidosis polyneuropathy (hATTR-PN). Inotersen PK and TTR level (PD) d...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Rosie Z., Collins, Jon W., Hall, Shannon, Ackermann, Elizabeth J., Geary, Richard S., Monia, Brett P., Henry, Scott P., Wang, Yanfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249474/
https://www.ncbi.nlm.nih.gov/pubmed/32286934
http://dx.doi.org/10.1089/nat.2019.0822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249474/
https://www.ncbi.nlm.nih.gov/pubmed/32286934
http://dx.doi.org/10.1089/nat.2019.0822

Ejemplares similares